References
- Hassel JC, Piperno-Neumann S, Rutkowski P, Baurain JF, Schlaak M, Butler MO, Sullivan RJ, Dummer R, Kirkwood JM, Orloff M, et al. Three-year overall survival with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2023. doi:10.1056/NEJMoa2304753.
- Wadman M. First malaria vaccine slashes early childhood mortality. doi:10.1126/science.adl5503.
- Datoo MS, Dicko A, Tinto H, Ouédraogo JB, Hamaluba M, Olotu A, Beaumont E, Ramos-Lopez F, Magloire Natama H, Weston S, et al. A Phase III randomised controlled trial evaluating the malaria vaccine candidate R21/Matrix-M™ in African children. SSRN [Preprint]. 2023. doi:10.2139/ssrn.4584076.
- Ling AL, Solomon IH, Landivar AM, Nakashima H, Woods JK, Santos A, Masud N, Fell G, Mo X, Yilmaz AS, et al. Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. 2023;623(7985):157–2. doi:10.1038/s41586-023-06623-2.
- Koseki T, Teramachi M, Koga M, Ko MSH, Amano T, Yu H, Amano M, Leyder E, Badiola M, Ray P, et al. A phase I/II clinical trial of intradermal, controllable self-replicating RNA vaccine EXG-5003 against SARS-CoV-2. medRxiv [Preprint]. 2023. doi:10.1101/2023.10.07.23296699.